Tag: psoriasis

1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis severity than methotrexate, though methotrexate remains an effective treatment for the condition. Evidence Rating: 2 (Good) Psoriasis is a highly debilitating chronic inflammatory skin disorder that affects up to 1.37% of children,...
1. Treatment with biologics in pediatric patients with moderate to severe psoriasis was significantly associated with greater reduction in psoriasis severity than methotrexate, though methotrexate remains an effective treatment for the condition. Evidence Rating: 2 (Good) Psoriasis is a highly debilitating chronic inflammatory skin disorder that affects up to 1.37% of...
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial 1. Study findings suggest that early administration of intravenous dexamethasone during acute respiratory distress syndrome may decrease duration of mechanical ventilation and mortality rates. Evidence Level: 1 (Excellent) Acute respiratory distress syndrome (ARDS), characterized by acute hypoxemic respiratory failure...
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial The ideal surgical excision margin for patients with thick (>2 mm) localized cutaneous melanomas is unclear, where the risk of recurrence must be weighed against excess morbidity resulting from...
1. In a posthoc analysis of 2, phase 3 randomized controlled trials of over 1000 patients with moderate-to-severe plaque psoriasis, tofacitinib (an oral Janus kinase inhibitor) treatment demonstrated significantly improved clinical nail psoriasis severity scores at 16 weeks compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Psoriasis is a...
1. In a prospective observational study of over 1100 patients with moderate to severe plaque psoriasis, long-term use (≥156 weeks) of apremilast was not associated with an increase in common or serious adverse events compared to short-term use (52 weeks). Evidence Rating Level: 2 (Good) Study Rundown: Psoriasis is a chronic,...
1. Risankizumab was associated with a significantly greater improvement in the primary endpoint of ≥90% reduction of the Psoriasis Area and Severity Index (PASI) score than ustekinumab. 2. Risankizumab was also associated with a significantly higher proportion of patients that experienced 100% reduction in the PASI score than ustekinumab. Evidence Rating...
1. In a retrospective cohort study of 12 patients with psoriasis, 8F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) demonstrated significantly increased arterial inflammation and subcutaneous adipose tissue inflammation compared to healthy controls. Evidence Rating Level: 3 (Average) Study Rundown: Psoriasis is a chronic, inflammatory skin disorder associated with an increased...
1. In a population-based cohort study of over 28 000 patients with psoriasis and their age- and sex-matched controls, patients with psoriasis was associated with an increased risk of avascular necrosis (AVN). 2. In patients with psoriasis, AVN risk was positively associated with male sex, age younger than 30 years,...
1. Patients with moderate-to-severe plaque psoriasis treated with ixekizumab had significantly greater improvements in psoriasis compared to those treated with placebo at the end of both 12-week induction and 60-week follow-up periods. 2. There was an increase in the rate of infections, particularly candidal in nature, in the patients exposed...